Michael Finn Henry, President & Founder EndoShunt, PhD Candidate Harvard Biodesign Lab SEAS

EndoShunt, provides trauma surgeons with a way to rapidly gain targeted control of abdominal hemorrhage. The company expects to receive FDA clearance in the next 18 months, following which it will begin a targeted launch in seven hospitals.

Lab-to-Launch Lounge

Thursday, September 18, 2025

Since his sophomore year of high school, Michael Finn Henry has been deeply involved in graduate-level research projects, demonstrating an early passion for innovation through scientific discovery. He studied mechanical engineering and minored in entrepreneurship at Vanderbilt University before coming to the Harvard John A. Paulson School of Engineering and Applied Sciences to pursue a PhD in Materials Science & Mechanical Engineering as member of the Harvard Biodesign Lab led by Dr. Conor Walsh.

As founder and President of EndoShunt, Michael is developing the world's first targeted endovascular hemorrhage control device specifically designed for trauma surgery to increase the time surgeons have to perform lifesaving procedures. He won the top prize in the Student Health and Life Sciences Track at the 2024 President's Innovation Challenge and has raised an $8.5 million Series A funding round. The company is now pursuing FDA 510(k) clearance and has already secured support from seven hospitals for their targeted launch phase.

Beyond his engineering pursuits, Michael is an elite speed climber who has competed for both Team USA and Canada in international competitions. He recently ran the Boston Marathon to fundraise for the Gillian Reny Stepping Strong Center for Trauma Innovation at Brigham and Women’s Hospital.

One piece of advice to Venturing@Harvard

Start by asking: Would anyone actually buy this? Then keep asking open-ended questions to uncover the real pain points. When the problem’s big enough, the solution becomes undeniable.